scholarly journals Evaluation of the Combined Application of Ethanol-Fixed and Formaldehyde-Fixed Neutrophil Substrates for Identifying Atypical Perinuclear Antineutrophil Cytoplasmic Antibodies in Inflammatory Bowel Disease

2009 ◽  
Vol 16 (4) ◽  
pp. 464-470 ◽  
Author(s):  
Maria Papp ◽  
Istvan Altorjay ◽  
Gabriella Lakos ◽  
Judit Tumpek ◽  
Sandor Sipka ◽  
...  
Keyword(s):  
Cathepsin G ◽  
Antineutrophil Cytoplasmic Antibodies ◽  
Enzyme Linked Immunosorbent Assay ◽  
Combined Application ◽  
Combined Use ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Perinuclear Anca ◽  
Different Sources ◽  
Formalin Fixed

ABSTRACT No clear guidelines for indirect immunofluorescence (IIF) detection and interpretation of antineutrophil cytoplasmic antibodies (ANCA) have been proposed for inflammatory bowel diseases (IBD). We evaluated the reliability of the combined use of ethanol- and formalin-fixed neutrophil substrates to identify atypical perinuclear ANCA (P-ANCA) by IIF under routine laboratory circumstances. A total of 204 IBD patients were assessed with four different fluorescent substrates in two distinct laboratories. Antibodies against myeloperoxidase, proteinase-3, and other specific granule proteins (elastase, lactoferrin, cathepsin G, lysozyme, and bactericidal permeability-increasing protein) were measured by an enzyme-linked immunosorbent assay. The combined application of ethanol- and formalin-fixed slides to detect atypical P-ANCA resulted in a lack of agreement between assays (κ, ≤0.39) in the interassay study and moderate agreement in the interobserver study (κ, 0.42). After atypical and typical P-ANCA patterns were combined, the consensus improved greatly. A total of 26.9% of patients were P-ANCA positive by at least two tests (44.3% of ulcerative colitis [UC] and 13.1% of Crohn's disease [CD] patients; P < 0.0001), while overall ANCA positivity was 22.5% to 34.8%. The combined application of ethanol-fixed and formaldehyde-fixed neutrophil substrates did not facilitate differentiation between P-ANCA and atypical P-ANCA, and the results were not consistent when substrates from different sources were used. Combining all P-ANCA ensures the highest sensitivity and specificity in differentiating UC from CD.

scholarly journals Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin

2021 ◽  
Vol Volume 14 ◽  
pp. 6409-6419
Author(s):  
Ying Cao ◽  
Yibei Dai ◽  
Lingyu Zhang ◽  
Danhua Wang ◽  
Wen Hu ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Oncostatin M ◽  
Combined Use ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Fecal Biomarkers

scholarly journals The method for diagnosing the activity of inflammatory bowel diseases based on a combination of electrical and viscoelastic parameters of erythrocytes and the level of fecal calprotectin

2021 ◽  
Vol 1 (6) ◽  
pp. 40-49
Author(s):  
M. V. Kruchinina ◽  
I. O. Svetlova ◽  
A. V. Azgaldyan ◽  
M. F. Osipenko ◽  
E. Yu. Valuiskikh ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Low Cost ◽  
Fecal Calprotectin ◽  
Cell Diameter ◽  
Average Cell ◽  
High Productivity ◽  
Viscoelastic Parameters ◽  
Combined Use ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Purpose of the work: to present a method for diagnosing the activity of inflammatory bowel diseases based on a combination of electrical and viscoelastic parameters of erythrocytes and the level of fecal calprotectin.Materials and methods. We examined 109 patients (37.7±11.7 years) with IBD (50 with ulcerative colitis, 41 with Crohn’s disease, 18 patients with unclassified colitis), of which 36 patients were examined in dynamics for 0.5–1 years, and 53 surveyed comparison groups. Taking into account the observation in dynamics in 109 cases, the presence of exacerbation of IBD was established and in 36 cases — remission of the diseases. The electrical and viscoelastic parameters of erythrocytes were studied by dielectrophoresis. The level of fecal calprotectin was determined by ELISA (R-Biopharm, Germany).Results. Differentiating values have been established for a number of erythrocyte parameters: average cell diameter, polarizability at a frequency of 106 Hz, the velocity of movement of cells towards electrodes, amplitude of erythrocyte deformation at a frequency of 106 Hz, the summarized indicators of rigidity, viscosity, electrical conductivity, position of the crossover frequency and the level of fecal calprotectin to distinguish patients with IBD in stages of exacerbation and remission. The proposed method for the combined use of erythrocyte parameters and the level of fecal calprotectin provided sufficient diagnostic accuracy: sensitivity 91.9%, specificity 93.1%, accuracy index 92.3%. The advantages of this approach are minimally invasiveness, high productivity, independence of the definition from the qualifications and experience of a specialist, low cost and labor intensity, and acceptability for the patient. This approach allows to establish the presence of exacerbation or remission, regardless of the nosological form of IBD.Conclusion. The combined use of electrical and viscoelastic parameters of erythrocytes and the level of fecal calprotectin is promising for determining the activity of the disease in patients with IBD.

Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases

2017 ◽  
Vol 55 (10) ◽  
Author(s):  
Sofia Farkona ◽  
Antoninus Soosaipillai ◽  
Panagiota Filippou ◽  
Christos Liaskos ◽  
Dimitrios P. Bogdanos ◽  
...  
Keyword(s):  
Clinical Utility ◽  
Solid Phase ◽  
Disease Onset ◽  
Enzyme Linked Immunosorbent Assay ◽  
Disease Phenotype ◽  
Serum Samples ◽  
Multicenter Studies ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Disease Location

AbstractBackground:Pancreatic autoantibodies (PABs) are detected in patients with inflammatory bowel disease (IBD). Their prevalence is higher in Crohn’s disease (CrD) than in ulcerative colitis (UC). Glycoprotein 2 (GP2) and, more recently, CUB and zona pellucida-like domain-containing protein 1 (CUZD1) have been identified as target autoantigens of PAB. The clinical utility of CUZD1 autoantibodies has only recently been assessed by indirect immunofluorescence (IIF) assays. In this study, we developed and validated novel immunoassays for the detection of CUZD1 autoantibodies.Methods:Recombinant CUZD1 protein was utilized as a solid-phase antigen for the development of two immunoassays for the detection of IgG and IgA CUZD1 autoantibodies. Serum samples from 100 patients with CrD, 100 patients with UC, 129 patients assessed for various autoimmune diseases (vADs) and 50 control individuals were analyzed.Results:Two immunofluorometric assays for the detection of IgG and IgA CUZD1-specific antibodies were developed. CUZD1 autoantibodies were detected in 12.5% (25/200) IBD patients, including 16% of patients with CrD and in 9% of patients with UC (CrD vs. UC, p<0.05), compared with 3.1% (4/129) patients suspected of having vADs (CrD vs. ADs, p<0.05; UC vs. ADs, p=0.08). CUZD1 autoantibody positivity was not found to be related to disease location, age of disease onset or disease phenotype.Conclusions:This is the first study to describe novel IgA and IgG CUZD1 autoantibody enzyme-linked immunosorbent assay. These immunoassays agree well with standard IIF techniques and can be utilized in multicenter studies to investigate the diagnostic and clinical utility of CUZD1 autoantibodies.

scholarly journals Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study

2021 ◽  
Vol 10 (12) ◽  
pp. 2653
Author(s):  
Anna Pękala ◽  
Rafał Filip ◽  
David Aebisher
Keyword(s):  
Maintenance Therapy ◽  
Response To Treatment ◽  
Assay Method ◽  
Enzyme Linked Immunosorbent Assay ◽  
Induction Treatment ◽  
Duration Of Treatment ◽  
Single Center Study ◽  
Bowel Diseases ◽  
Antibody Titers ◽  
Inflammatory Bowel

Reports of the prevalence of antibodies to infliximab (anti-drug antibodies, ADA) are inconsistent due in part to the various assay formats used to monitor immunogenicity in the clinic and under clinical trial settings. This study aimed to determine the frequency of ADA in patients with inflammatory bowel disease (IBD) during induction and maintenance therapy with biosimilar infliximab (CT-P13) using the ELISA (enzyme-linked immunosorbent assay) method. In this prospective single-center study, we analyzed the incidence of ADA and the relationship between the presence of ADA and the following variables: gender, type of disease, immunosuppressive therapy used, and duration of treatment. A total of 84 patients with IBD received CT-P13 and were followed up for an average of 7 months. We found ADA in 50% of the patients with undetectable levels of the drug. The percentage of persons with antibodies detected during induction treatment was 11.3% compared to 9.6% during maintenance therapy. The analysis showed no relationship between response to treatment and antibody titers (p = 0.381). The study showed a statistically significant relationship between undetectable levels of CT-P13 and the presence of ADA at week 6 of therapy (i.e., ADA were detected in all the patients with undetectable levels of CT-P13). Patients with IBD and undetectable levels of CT-P13 before administration of the third induction dose were at high risk of the presence of anti-drug antibodies as well as primary non-response.

scholarly journals Optimization of approaches to the treatment of mild to moderate ulcerative colitis

2021 ◽  
Author(s):  
С.С. Белоус ◽  
О.В. Князев
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Practice ◽  
Autoimmune Disease ◽  
Prolonged Release ◽  
Ph Values ◽  
Combined Use ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Ph Dependent ◽  
Systemic Drug

Язвенный колит – аутоиммунное заболевание толстой кишки, проявляющееся развитием неспецифического воспаления его слизистой оболочки с обязательным поражением прямой кишки. Наиболее часто в клинической практике встречается левосторонний язвенный колит, легкая или среднетяжелая атака. Оптимальным способом лечения таких пациентов являются месалазины, однако применение препарата с рН-зависимой оболочкой может быть ограничено в связи с большим разнообразием значений рН у пациентов с воспалительными заболеваниями кишечника. Препаратами выбора в таких ситуациях являются покрытые этилцеллюлозой микрогранулы месалазина с пролонгированным высвобождением, позволяющие достигнуть максимального терапевтического эффекта. Для улучшения результатов терапии месалазинами необходимо комбинированное применение местного и системного препарата. При неэффективности данного подхода в качестве альтернативы системным глюкокортикостероидам можно рассмотреть вопрос о назначении будесонида ММХ с новой мультиматриксной системой высвобождения месалазина (multimatrix system, ММХ). Ulcerative colitis is an autoimmune disease of the colon, manifested by the development of non-specific inflammation of its mucous membrane with a mandatory lesion of the rectum. The most common in clinical practice is left-sided ulcerative colitis, a mild or moderate attack. The optimal treatment for such patients is mesalazine, but the use of the drug with a pH-dependent shell may be limited due to the large variety of pH values in patients with inflammatory bowel diseases. The drugs of choice in such situations are ethylcellulose-coated mesalazine microgranules with prolonged release, which allow to achieve the maximum therapeutic effect. To improve the results of mesalazine therapy, the combined use of a local and systemic drug is necessary. If this approach is ineffective, the use of budesonide MMH may be considered as an alternative to systemic glucocorticosteroids. Keywords: mesalazine, treatment scheme, therapy, ulcerative colitis, proctitis, left-side colitis, budesonide, suppositoria, delivery system, MMX.

Sign in / Sign up

Export Citation Format

Share Document